NEW YORK (GenomeWeb News) – Cellular Dynamics International has priced its initial public offering at $12 per share, the stem cell technology firm announced late Wednesday.

Its shares are anticipated to trade on the Nasdaq under ticker symbol "ICEL." CDI is offering about 3.8 million shares in its IPO. Additionally it granted its underwriters a 30-day option to purchase an additional 576,900 shares.

JP Morgan Securities is the sole book-running manager on the offering. Cowen &Co and Leerking Swann are co-managers.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.